Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SPEVIGO safely and effectively. See full prescribing information for SPEVIGO. SPEVIGO® (spesolimab-sbzo) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.
- generic_name
- spesolimab-sbzo
- product_names
- spesolimab-sbzo
- ndc
- 0597-0035, 0597-0620, 0597-7705, 0597-0035-10, 0597-0620-10, 0597-0620-20, 0597-7705-38, 0597-7705-72, 0597-7705-41
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en